Boehringer

Boehringer expands production site in Greece for new medicine

Retrieved on: 
Thursday, January 11, 2024
Patient, Professional, Corporate headquarters, Chronic liver disease, Boehringer, Scleroderma, Heart failure, Government, Mental health, Research and development, Pulmonary fibrosis, Chronic kidney disease, CRM, EUR, Boehringer Ingelheim, Workforce

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced a further expansion and upgrade of its plant in Koropi, Greece.

Key Points: 
  • Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced a further expansion and upgrade of its plant in Koropi, Greece.
  • Greek Prime Minister Kyriakos Mitsotakis attended the groundbreaking ceremony at the Koropi site today, alongside the Minister of State, the Minister of Health and the Minister of Development.
  • In 2020, the company announced multi-year investments to expand the site and its production capacity.
  • The Koropi plant is the only industrial facility of a multinational pharmaceutical company in Greece producing innovative medicines.

Boehringer Ingelheim licenses multiple Dark Antigens® from Enara Bio to develop off-the-shelf immunotherapies for non-small cell lung cancer (NSCLC)

Retrieved on: 
Thursday, January 4, 2024
Dark, Science, Partnership, Protein, Neoplasm, Antigen, Boehringer Ingelheim, TCR, Vaccine, Lung cancer, Boehringer, Cancer, Genome, Patient, Exercise, Senior

Enara Bio today announces that Boehringer Ingelheim has exercised its option to license a number of cancer antigens discovered and validated through the ongoing collaboration using Enara Bio’s Dark Antigen discovery platform, EDAPT®.

Key Points: 
  • Enara Bio today announces that Boehringer Ingelheim has exercised its option to license a number of cancer antigens discovered and validated through the ongoing collaboration using Enara Bio’s Dark Antigen discovery platform, EDAPT®.
  • Based on the licensed antigens, Boehringer intends to develop novel off-the-shelf vaccines for the treatment of patients with NSCLC.
  • Under the collaboration, Enara Bio’s EDAPT platform is being used to discover and validate Dark Antigens in multiple solid tumor types.
  • During the antigen validation work package, Enara Bio demonstrated that the licensed antigens have several attractive characteristics as targets for immunotherapies.

Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases

Retrieved on: 
Wednesday, January 3, 2024
RNA, RNA interference, Liver, Partnership, NASH, Boehringer Ingelheim, Cirrhosis, Hepatocyte, Small RNA, Boehringer, Research, Messenger, USD, DSM-IV codes, CRM, Liver failure, Liver cancer, Patient, Therapy, Senior, Pharmaceutical industry

INGELHEIM, Germany, MÖLNDAL, Sweden and KUNSHAN, China, Jan. 3, 2024 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).

Key Points: 
  • INGELHEIM, Germany, MÖLNDAL, Sweden and KUNSHAN, China, Jan. 3, 2024 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).
  • More than 440 million people worldwide are estimated to live with NASH, an inflammatory liver disease that is caused by accumulation of fat in the liver.
  • Over time, NASH causes scar tissue formation, which in many cases leads to liver cirrhosis and related serious complications, including liver failure or liver cancer.
  • We are very pleased about the opportunity to work with Boehringer Ingelheim to develop new solutions for people living with NASH."

Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases

Retrieved on: 
Wednesday, January 3, 2024
RNA, RNA interference, Liver, Partnership, NASH, Boehringer Ingelheim, Cirrhosis, Hepatocyte, Small RNA, Boehringer, Research, Messenger, USD, DSM-IV codes, CRM, Liver failure, Liver cancer, Patient, Therapy, Senior, Pharmaceutical industry

INGELHEIM, Germany, MÖLNDAL, Sweden and KUNSHAN, China, Jan. 3, 2024 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).

Key Points: 
  • INGELHEIM, Germany, MÖLNDAL, Sweden and KUNSHAN, China, Jan. 3, 2024 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).
  • More than 440 million people worldwide are estimated to live with NASH, an inflammatory liver disease that is caused by accumulation of fat in the liver.
  • Over time, NASH causes scar tissue formation, which in many cases leads to liver cirrhosis and related serious complications, including liver failure or liver cancer.
  • We are very pleased about the opportunity to work with Boehringer Ingelheim to develop new solutions for people living with NASH."

Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Potential Treatment of Advanced or Metastatic Large-Cell Neuroendocrine Carcinoma of the Lung

Retrieved on: 
Wednesday, November 29, 2023
Partnership, Food, Drug discovery, Boehringer Ingelheim, FDA, Lung, Disease, Boehringer, News, Orphan drug, NEC, Carcinoma, OBT, SCLC, Patient, ADC, DLL3, Fast Track, Pharmaceutical industry

BI 764532 is an investigational DLL3/CD3 IgG-like T-cell engager for potential treatment of patients with LCNEC-Lung that is being developed by Boehringer Ingelheim.

Key Points: 
  • BI 764532 is an investigational DLL3/CD3 IgG-like T-cell engager for potential treatment of patients with LCNEC-Lung that is being developed by Boehringer Ingelheim.
  • The discovery of BI 764532 (OBT620) was enabled through a successful partnership initiated in 2013, leveraging OBT’s proprietary OGAP® drug discovery platform for identification of the DLL3 antigen and Boehringer Ingelheim’s longstanding expertise in oncology and development of biotherapeutics.
  • BI 764532 was also granted Orphan Drug designation by the FDA for the treatment of SCLC, and is currently being investigated in a Phase 2 study, ‘DAREON™-5’ ( NCT05882058 ), in patients with relapsed/refractory extensive-stage SCLC and other relapsed/refractory NEC.
  • Christian Rohlff, Chief Executive Officer of OBT, commented: “We are delighted about the clinical development to help address unmet needs for people living with small cell lung cancer and other neuroendocrine carcinomas.

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

Retrieved on: 
Wednesday, November 22, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Boehringer, Trichloroethylene, Acquisition, Innovation, Ingelheim am Rhein, Potyvirus, Boehringer Ingelheim, Tissue, Cancer, Innovation Unit, Patient, Bi-specific T-cell engager, Bacteria, Immunotherapy, CHF, Pharma, Fine chemical, Vaccine, Allschwil

Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF.

Key Points: 
  • Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF.
  • T3 Pharma has developed a proprietary therapy platform that uses live bacteria to deliver immune-modulating proteins to cancer cells and tumor micro-environments.
  • “The acquisition of T3 Pharma will significantly expand our immuno-oncology pipeline portfolio and is synergistic with many of our existing R&D programs.
  • Boehringer Ingelheim is adopting a comprehensive approach to cancer therapy development including both cancer cell-directed and immuno-oncology approaches.

Ten63 Therapeutics Announces Multi-Target Drug Discovery Collaboration with Boehringer Ingelheim

Retrieved on: 
Wednesday, December 6, 2023
Boehringer, Boehringer Ingelheim, Life expectancy, ADME, Therapy, Patient, Chemistry, Partnership, Metabolism, Drug discovery, Drug development, Fine chemical

DURHAM, N.C., Dec. 6, 2023 /PRNewswire/ -- Ten63 Therapeutics, a biotechnology company unlocking previously undruggable targets by leveraging proprietary algorithms combining interpretable generative AI and physics-based models, announced today a multi-target drug discovery collaboration with Boehringer Ingelheim. The new partnership is aiming to enable the discovery of novel therapeutic molecules, to address diseases that are out of reach of conventional drug discovery, i.e. diseases with high unmet patient needs.

Key Points: 
  • DURHAM, N.C., Dec. 6, 2023 /PRNewswire/ -- Ten63 Therapeutics, a biotechnology company unlocking previously undruggable targets by leveraging proprietary algorithms combining interpretable generative AI and physics-based models, announced today a multi-target drug discovery collaboration with Boehringer Ingelheim.
  • The new partnership is aiming to enable the discovery of novel therapeutic molecules, to address diseases that are out of reach of conventional drug discovery, i.e.
  • The collaboration will apply Ten63's computational drug discovery engine, BEYOND, to discover novel molecules for multiple Boehringer Ingelheim targets in diverse indications, and leverage Boehringer Ingelheim's expertise in pre-clinical discovery and drug development.
  • The BEYOND platform is composed of a suite of proprietary algorithms designed to enable drug discovery for targets that are difficult for conventional drug discovery technologies.

Latest Updates of Viva's Portfolio Companies

Retrieved on: 
Monday, December 4, 2023
JAK1, NMPA, Patient, American College of Rheumatology, Bayer, SUA, Neoplasm, Cataract, Therapy, URAT1, MBA, Cancer, Health care, Inflammation, Fabry disease, Safety, Toxicity, IND, SHP2, USD, Strong, Letter, Woman, EA Phenomic, Pharmacokinetics, VBI, HER2, MPM, Antibody, GCS, GEJ, Boehringer, Research, Plasma, Boehringer Ingelheim, Clinical trial, Investment, MaRS Discovery District, FDA, American College, Phase II, Clostridial necrotizing enteritis, Selective, MPH, ACR, EGFR, Pharmaceutical industry, Astellas Pharma, Phase, Deka, Facet joint arthrosis

TORONTO & WALTHAM, Mass.--(BUSINESS WIRE)--On Nov. 29th, Phenomic AI ("Phenomic"), invested and incubated by Viva BioInnovator (VBI), announced that they have entered into a strategic collaboration and licensing agreement with Boehringer Ingelheim to discover targets important in stroma-rich cancers. The partners will leverage Phenomic's expertise in target identification and stromal biology based on its scTx® single-cell transcriptomics platform which will greatly enhance Boehringer's efforts to develop first-in-class medicines to transform the lives of people with cancer by delivering meaningful advances with the ultimate goal to cure a range of cancers. Phenomic will receive upfront and near-term payments of approximately $9 million including research funding and collaboration milestones. Phenomic is also eligible to receive more than USD $500 million in licensing fees as well as clinical, regulatory and commercial milestones in addition to royalties on future product sales.

Key Points: 
  • HONG KONG, Dec. 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development.
  • This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.
  • Recently, Viva's portfolio companies have new updates.
  • Phenomic will receive upfront and near-term payments of approximately $9 million including research funding and collaboration milestones.

Mestag Therapeutics announces the appointment of expert advisors Dr. Cassandra Choe-Juliak, Dr. Greg Elson and Samantha Vieira MBA

Retrieved on: 
Thursday, October 12, 2023
Bachelor of Science, Ipsen, Bispecific monoclonal antibody, Affimer, MBA, Receptor (biochemistry), Acquisition, Doctor of Philosophy, MS, Development, Henley Business School, Breast, PMP, Multiple myeloma, University, AMAL, VCU Medical Center, Boehringer, Glenmark Pharmaceuticals, Biosimilar, Therapy, Georgetown University, Medical college, Merck, University of the Witwatersrand, Nightstar, Publication, Biogen, Lung, Selinexor, EMBA, Boehringer Ingelheim, XPO, Patient, Pharmaceutical industry, Molecular Immunology, Physiology, MD

"Mestag is honored to appoint Dr. Choe-Juliak, Dr. Elson and Ms Vieira to our advisory team.

Key Points: 
  • "Mestag is honored to appoint Dr. Choe-Juliak, Dr. Elson and Ms Vieira to our advisory team.
  • Cassandra Choe-Juliak, MD, MS, has spent more than 17 years in oncology medical affairs and clinical drug development.
  • Greg Elson, PhD, is co-founder and managing partner at Prevail Biopharma Solutions, and Chief Technology Officer at Alentis Therapeutics.
  • Samantha holds an EMBA from Henley Business School and BSc (Honours) in Physiology from University of the Witwatersrand, South Africa.

Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Treatment of Extensive Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancers

Retrieved on: 
Tuesday, October 3, 2023
Partnership, Boehringer, Glomus tumor, American Society of Clinical Oncology, OBT, Fast Track, SCLC, ASCO, U.S. FDA, Boehringer Ingelheim, DLL3, Patient, Antibody-drug conjugate, Annual general meeting, Drug discovery, Diagnosis, ADC, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, Disease, Pharmaceutical industry

BI 764532 is an investigational DLL3/CD3 IgG-like T-cell engager for treatment of patients with SCLC and other neuroendocrine tumors that is being developed by Boehringer Ingelheim.

Key Points: 
  • BI 764532 is an investigational DLL3/CD3 IgG-like T-cell engager for treatment of patients with SCLC and other neuroendocrine tumors that is being developed by Boehringer Ingelheim.
  • Encouraging data were presented from the Phase I first-in-human dose-escalation trial at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting.
  • These Phase I data demonstrated a clinically acceptable safety profile and early efficacy in patients with DLL3-positive ES-SCLC and epNECs.
  • This is tremendously exciting for OBT, as it shows the real impact this partnership has for patients in need.